.Attributes Medicine, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) procedure of individuals with HER2+ enhanced bosom cancer and also active or secure human brain metastases revealed constant intracranial activity and wide spread effectiveness of T-DXd.